Ranitidine Disphar

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ranitidine Disphar

What is Ranitidine Disphar?

Ranitidine Disphar is a medication that belongs to a class of drugs known as histamine-2 (H2) receptor antagonists. It is used to manage and treat conditions related to the overproduction of stomach acid. By targeting specific receptors in the lining of the stomach, the medication works to reduce the total volume and concentration of acid secreted during digestion and at rest.

Primary Uses

This medication is primarily used to address issues involving the upper gastrointestinal tract. It is commonly utilized for the following purposes:

  • Acid Reflux and Heartburn: Providing relief from the burning sensation caused by stomach acid rising into the esophagus.
  • Gastric and Duodenal Ulcers: Assisting in the healing process of ulcers located in the stomach or the upper part of the small intestine, and helping to prevent their recurrence.
  • Zollinger-Ellison Syndrome: Managing rare conditions where the stomach produces excessive amounts of acid.
  • Gastroesophageal Reflux Disease (GERD): Managing the symptoms and complications associated with chronic acid reflux.

How it Functions

The active ingredient in Ranitidine Disphar blocks the action of histamine on the parietal cells in the stomach wall. Histamine is one of the primary triggers that signals these cells to release hydrochloric acid. By inhibiting this process, the medication lowers the acidity levels within the stomach, which helps to alleviate pain and allows the digestive lining to recover from irritation or ulceration.

Regulatory References

  1. NCI Drug Dictionary
  2. National Cancer Institute (NCI)
  3. MeSH: Histamine H2 Antagonists
  4. NIH MeSH Database

What side effects are possible with Ranitidine Disphar?

Possible Side Effects and Safety Information

The safety profile of Ranitidine Disphar is categorized according to established regulatory standards, outlining documented adverse reactions by frequency and affected organ system. This information is derived exclusively from official governmental sources, such as the FDA and EMA labeling.

Adverse effects are grouped into frequency tiers: Common, Uncommon, Rare, and Very Rare.


Adverse Reactions by Frequency

Classification Examples of Officially Documented Effects
Common Headache (may be severe), Dizziness
Uncommon Gastrointestinal disturbances (e.g., abdominal pain, constipation, diarrhea, nausea, vomiting), Reversible changes in liver function tests
Rare Hypersensitivity reactions (e.g., urticaria, rash, bronchospasm), Acute pancreatitis, Reversible blurred vision
Very Rare Serious blood disorders (e.g., agranulocytosis, pancytopenia), Hepatitis, Anaphylactic shock, Cardiac arrhythmias

Serious Adverse Reactions and Systemic Safety

Official labeling highlights severe systemic reactions, including Hepatitis (cholestatic, hepatocellular, or mixed), severe Blood Dyscrasias (disorders affecting white blood cells or platelets), and Anaphylactic Shock. These effects represent risks across various System-Organ Classes, such as the Hepato-biliary, Blood and Lymphatic System, and Immune systems.

Population-Specific Safety Notes

The regulatory profile includes specific considerations for certain patient groups. Older adults and severely ill patients have an increased risk of neurological effects, such as mental confusion, hallucinations, and depression. For individuals with renal impairment, the official documentation notes that reduced clearance of the active substance can lead to elevated levels, which may increase the potential for adverse effects. The medicine is also restricted and should be avoided in patients with a history of acute porphyria.

Overdose and Emergency Response

Overdose and when to seek help

The officially documented overdose profile for Ranitidine Disphar (Ranitidine Hydrochloride) is derived from regulatory labeling and primarily involves effects on the central nervous system (CNS) and the cardiovascular system.

Documented Overdose Presentations

Physiological System Documented Manifestations
Central Nervous System Confusion, agitation, hallucinations, lack of coordination (ataxia), dizziness, drowsiness, and slurred speech.
Cardiovascular System Abnormal heartbeat (including rapid or slow rates), and low blood pressure (hypotension).
Systemic/Other Sweating, flushing, fainting, nausea, vomiting, and diarrhea.

Required Emergency Actions and Monitoring

When to Seek Urgent Help: Immediate emergency medical attention is required in the event of suspected overdose or exposure to excessive doses, as stated in regulatory guidelines. This includes mandatory instruction to contact a Poison Control Center right away.

Severe Outcome Triggers: If the individual has collapsed, is having a seizure, is experiencing trouble breathing, or cannot be awakened, emergency services must be contacted immediately.

Supportive Management: There is no specific antidote officially identified for Ranitidine overdose. Management focuses on symptomatic and supportive treatment, including the use of activated charcoal and procedures such as ECG monitoring and the provision of Intravenous (IV) fluids.

Population-Specific Considerations: An increased risk of developing severe CNS effects is officially noted, occurring predominantly in severely ill elderly patients and those with impaired renal function.

Therapeutic Uses of Ranitidine Disphar

Quick Facts

  • Addresses: Symptoms related to excessive stomach acid production.
  • Therapeutic Uses: Management of gastric and duodenal ulcers.
  • Specific Conditions: Assists in the care of gastroesophageal reflux disease (GERD).
  • Also Employed For: Management of Zollinger-Ellison syndrome.

What Ranitidine Disphar Treats: Main Uses and Benefits

Ranitidine Disphar is indicated for the management of conditions where the stomach produces an elevated amount of acid. This medication is utilized to support the treatment of ulcers in both the stomach (gastric ulcers) and the small intestine (duodenal ulcers). It may also be administered to assist in preventing the recurrence of these ulcers after initial healing has occurred.

The medication is employed in the therapeutic care of gastroesophageal reflux disease (GERD). In individuals with GERD, it may contribute to the alleviation of symptoms associated with the backward flow of stomach acid into the esophagus, such as persistent heartburn and injury to the lining of the food pipe (esophagus).

Additionally, Ranitidine Disphar is used in the management of pathological hypersecretory conditions, which involves situations where the stomach creates excessive amounts of acid. This includes the care of Zollinger-Ellison syndrome, a condition where tumors cause increased production of gastric acid.

Eligibility and Restrictions for Use

Ranitidine Disphar, an H2-receptor antagonist, was previously used to reduce stomach acid for conditions such as heartburn, Gastroesophageal Reflux Disease (GERD), and to treat and prevent stomach ulcers.


Who Can Use Ranitidine

Before market withdrawal due to safety concerns, ranitidine was typically used by:

  • Adults and Children (usually over 12 years of age, though prescription use for younger children was possible).
  • Individuals with conditions linked to excess stomach acid, including GERD, duodenal ulcers, and Zollinger-Ellison syndrome.

Patients with kidney or liver disease required careful dose adjustment and monitoring due to the drug's metabolism and excretion.


Who Cannot Use Ranitidine (Contraindications)

Ranitidine is contraindicated and should not be used by patients who have a known hypersensitivity or allergy to ranitidine or other H2-receptor antagonists (like famotidine or cimetidine). Additionally, it was generally avoided in patients with:

  • A history of acute porphyria (a rare blood disorder), as it may trigger an attack.
  • Underlying stomach malignancy, as symptom relief from ranitidine could mask the condition.

Consultation with a healthcare professional was always necessary for pregnant or breastfeeding individuals, the elderly, and those taking other medications that interact with ranitidine.

What should I know about interactions with other medicines?

Ranitidine’s officially documented interaction profile is based on two primary pharmacokinetic mechanisms. The main effect—the reduction of gastric acid—alters the stomach's pH, which directly affects the absorption of many co-administered medicines. Drugs that require an acidic environment for dissolution experience a documented decrease in plasma exposure. This includes substances like Ketoconazole, Atazanavir, and Erlotinib.

Conversely, this same mechanism results in an officially documented increase in the plasma concentration of certain co-administered substances, such as oral Midazolam and Triazolam.

Second, ranitidine competes with certain medicines for the renal organic cation transport system. This process is responsible for the documented reduced renal clearance and resultant increased plasma levels of substances like Procainamide.

Regulatory documents mandate specific procedural constraints for these interactions. Atazanavir and Erlotinib require a specific timing separation of several hours from ranitidine administration. Co-administration with Warfarin may result in documented altered prothrombin time, requiring close observation. Additionally, no clinically significant interaction with food or alcohol is noted in official sources.

Mechanism of Action

How Ranitidine Disphar Works

Ranitidine Disphar functions by precisely targeting the signaling pathways involved in gastric acid secretion. Its mechanism is centered on the pharmacological domain of receptor antagonism, specifically within systems that mediate secretory responses.

Histamine H2 Receptor Antagonism

The drug acts as a competitive antagonist at the histamine H2 receptors located on the basal membrane of gastric parietal cells. By binding to these sites, Ranitidine Disphar prevents the attachment of endogenous histamine. This blockade suppresses the G-protein coupled signaling cascade, inhibiting the increase in intracellular cyclic adenosine monophosphate (cAMP) and subsequent protein kinase A (PKA) activity. This step is critical for stimulating the H^+/ K^+-ATPase (proton pump), the final step in acid secretion.


Modulation of Gastric Secretory Pathways

By modifying the early molecular steps that activate the parietal cell, the drug imposes a systemic alteration on the secretory process. This mechanism results in a diminution of H^+ secretion into the stomach lumen, modifying the overall secretory dynamics and leading to resultant physiological changes that alter pH dynamics.

Dosage and Administration Information

Administration Scope

Route of Administration: The official administration routes are Oral (tablets, syrup) and Parenteral (Intravenous or Intramuscular injection), with the parenteral form generally reserved for hospitalized patients.

Dosing Schedule (Adults):

Condition Standard Labeled Regimen Duration Pattern
Acute Ulcer Treatment 150 mg twice daily ( b.i.d.) OR 300 mg once daily ( h.s.) Short-term (typically up to 4–8 weeks)
Maintenance Ulcer Therapy 150 mg once daily ( h.s.) at bedtime Long-term (up to 1 year)
Hypersecretory Conditions 150 mg twice daily, adjustable up to 6 g per day Based on acid secretion measurement

Timing in Relation to Meals: For prescription use, oral dosing is generally not required to be timed in relation to meals. However, the once-daily dose for acute treatment and maintenance therapy is often specifically directed to be taken at bedtime ( h.s.).

Preparation Requirements (Parenteral): The 50 mg intravenous bolus dose must be diluted prior to injection and administered slowly over a period of at least two minutes.

Age-Group and Condition Rules:

  • Pediatric Patients (1 month to 16 years): Oral dosing for ulcers is weight-based, typically 2 to 4 mg/kg twice daily, with a maximum dose of 300 mg/day.
  • Renal Impairment: Dose modification is required in patients with impaired kidney function ( creatinine clearance < 50 mL/min), where the standard oral dose is reduced to 150 mg every 24 hours.

Resulting Procedural Structure

Connection to the overall use protocol (4 sentences): The official instructions establish a structured usage protocol that differentiates the administration method based on the patient's care setting, utilizing the parenteral route exclusively in the hospital environment. The protocol mandates clear numerical dosing ranges and frequencies for both the acute treatment phase and the long-term maintenance phase. Furthermore, the instructions explicitly require dose reduction in specific populations, such as pediatric patients and those with documented renal impairment. This framework ensures a standardized approach to using the medication.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Ranitidine Disphar

The research overview for ranitidine is based on clinical data collected across various study types, including randomized controlled trials and meta-analyses. Research has explored outcomes related to physical discomfort and systemic imbalance in individuals with conditions associated with acute or disruptive episodes linked to high gastric acid.


Evidence for Ulcer Healing: Duodenal and Gastric Ulcers

The research base for ulcer healing primarily involved short-term Randomized Controlled Trials (RCTs) in adult patients with endoscopically confirmed ulcers. Researchers studied the compound both against a placebo and in head-to-head comparisons with other treatments. The outcomes tracked included the endoscopic healing rate, which was used to measure the ulcer crater's status after a defined treatment period, typically 4 to 8 weeks.

Research describes one area of recognized limitation involves the context of comparative trials that examined outcomes against other acid-suppressive classes. Additionally, historical research was conducted before H. pylori eradication became standard care, which may influence how past long-term outcomes are understood today.

Research on Preventing Ulcer Recurrence

Research explored long-term follow-up using randomized, controlled studies that monitored recurrence risk in adult populations. These trials examined recurrence risk, defined by either symptomatic or endoscopically confirmed recurrence, over time intervals such as six months or longer. Findings describe patterns observed where the continued use of the compound was observed in some studies to be associated with changes measured over the long-term time intervals.


Evidence for Gastroesophageal Reflux Disease (GERD)

Studies exploring outcomes related to GERD primarily used short-term RCTs and systematic reviews. The research focused on conditions involving periods of heightened symptoms and outcomes linked to inflammatory or irritative states of the esophagus. Findings indicate that while studies describe changes measured in symptoms, findings were mixed when comparing the status to the results of other acid-suppressive agents.


Evidence in Different Patient Groups and Research Gaps

Research explored the compound in specific groups, including studies focused on infants and children with reflux symptoms. The research primarily involves adult populations with uncomplicated peptic ulcer disease. Comparative evidence is a recognized limitation; research describes that many analyses focus on this compound was observed alongside other acid-suppressing agents, meaning comparative evidence is lacking for some scenarios. Long-term effects are not fully established outside of historical maintenance studies for duodenal ulcers.

Key Studies & References

  1. Standard-Dose Proton Pump Inhibitors in the Initial Non-eradication Treatment of Duodenal Ulcer: Systematic Review, Network Meta-Analysis, and Cost-Effectiveness Analysis
  2. Medical management of gastro-esophageal reflux in healthy infants (Outlines limited evidence for H2RAs in pediatric populations)

Frequently Asked Questions (FAQ)

Common questions about Ranitidine Disphar (FAQ)


Q: How quickly should Ranitidine Disphar start working for heartburn?

A: Official regulatory documents indicate that the clinical effect of reducing stomach acid can begin relatively quickly, though peak levels in the blood may take 2 to 3 hours. Some formulations, such as effervescent tablets, may be associated with a more immediate onset of action.


Q: Is it normal to feel a bit dizzy after taking Ranitidine Disphar?

A: According to official labeling, dizziness is listed as a common adverse reaction associated with the use of this medication. However, individuals experiencing severe dizziness along with heartburn are generally advised in patient information to seek professional medical evaluation.


Q: What are some food or drink interactions to watch out for with Ranitidine Disphar?

A: Official product information notes that the absorption of Ranitidine Disphar is not significantly affected by food or common antacids. Furthermore, regulatory sources generally state that there is no clinically significant interaction noted with food or alcohol when taking this medication.


Q: Why did some versions of Ranitidine get recalled or taken off the market?

A: Ranitidine products were recalled and withdrawn from many markets due to the detection of an impurity called N-nitrosodimethylamine (NDMA). This substance was found above acceptable levels in some products, with regulatory agencies stating that levels of this impurity could increase over time and when stored at higher temperatures.


Q: What happens if you miss a dose of Ranitidine Disphar?

A: Patient information generally states that if a dose is missed, it should be taken as soon as it is remembered. However, if it is close to the time for the next scheduled dose, the individual is usually advised to skip the missed dose and not double up to make up for the one they forgot.


Q: Is it okay to crush or chew Ranitidine Disphar tablets?

A: Specific instructions vary by the exact form of the medicine. Instructions for effervescent tablets often specify that they must be dissolved in water and should not be broken or chewed. For other solid tablets, the official information does not typically include instructions to crush or chew non-effervescent tablets.


Q: Can you drive or operate machinery after taking Ranitidine Disphar?

A: Official labeling lists common side effects like dizziness and rare effects like reversible mental confusion. Because of the possibility of these effects, official warnings suggest caution when performing activities that require mental alertness, such as driving or operating machinery.


Q: Does Ranitidine Disphar have an impact on kidney function?

A: Regulatory documents note that the medication may rarely cause an elevation in blood markers such as serum creatinine or conditions like a specific type of kidney inflammation. These changes have been described as slight and typically returned to normal with continued treatment.


Q: Is Ranitidine Disphar safe for pregnant or breastfeeding individuals to take?

A: The drug is classified by the FDA as Pregnancy Category B. This designation typically indicates that animal studies have not shown risk, but adequate and well-controlled studies in pregnant women have not been conducted. It is also known to be excreted into human milk, so caution is advised during breastfeeding.


Q: Are there any warning signs for allergic reactions to Ranitidine Disphar?

A: Official product information highlights signs of a serious allergic reaction, which include hives, difficult breathing, and swelling of the face, lips, tongue, or throat. Official patient information generally advises that these signs warrant immediate medical help.


Q: Is Ranitidine Disphar only available by prescription?

A: Historically, Ranitidine has been approved and sold in both prescription forms, typically for conditions like ulcers, and lower-strength over-the-counter (OTC) forms for common heartburn. Current availability may vary depending on the specific regulatory status in your country.


Q: What ingredients are in Ranitidine Disphar besides the active component?

A: The active ingredient is Ranitidine Hydrochloride. Official labeling lists various inactive ingredients, or excipients, used in the final product. These can include substances like lactose monohydrate, magnesium stearate, binders, and colorants.


Q: Is there a generic version of Ranitidine Disphar?

A: Yes, regulatory bodies such as the FDA have approved numerous generic versions of Ranitidine Hydrochloride. These generic products are generally considered interchangeable with the brand-name version unless they were also subject to market withdrawal or recall.


Q: How long does the effect of Ranitidine Disphar last?

A: The elimination half-life of ranitidine is approximately 2.5 to 3 hours, which is the time it takes for half of the drug to leave the body's circulation. Dosing regimens, such as taking the medicine twice daily, are designed to maintain an effective level of acid suppression based on this duration.


Q: How long can you take Ranitidine Disphar continuously?

A: Regulatory documents for some indications, such as maintenance therapy for ulcers, allow for long-term use. This period may typically extend up to one year. Its use for periods up to one year is based on studies overseen by healthcare professionals.


Q: Is it common to experience diarrhea or constipation with Ranitidine Disphar?

A: Gastrointestinal disturbances, which include both diarrhea and constipation, are officially classified as uncommon side effects. This means they occur in less than 1% of patients in clinical trials.


Q: Can Ranitidine Disphar be taken before bed?

A: Yes, the official dosing schedule for certain conditions, particularly maintenance therapy and some acute treatments for ulcers, often specifically directs the once-daily dose to be taken at bedtime (often abbreviated as h.s.).


Q: What is the best time of day to take Ranitidine Disphar?

A: The timing of the dose depends on the condition being addressed. For maintenance treatment of ulcers, the drug is often prescribed to be taken once daily at bedtime. For acute treatment, it is typically taken twice daily, which may be timed to best fit your routine.


Q: Does Ranitidine Disphar affect vitamin absorption?

A: Official labeling explicitly notes that the drug's acid-reducing mechanism can alter the absorption of certain co-administered medicines that require an acidic stomach environment. However, official sources do not contain an explicit statement regarding its effect on general vitamin absorption.


Q: Can Ranitidine Disphar be used by people with liver issues?

A: Caution should be observed if there is liver dysfunction, as the medication is processed by the liver. Official warnings note that it may rarely cause reversible changes in liver function tests or conditions like hepatitis.


Q: What is the difference in mechanism between Ranitidine Disphar and omeprazole?

A: Ranitidine is categorized as an H2-receptor antagonist, which blocks a signal (histamine) that triggers acid production. In contrast, Omeprazole is a proton pump inhibitor (PPI), which works by irreversibly blocking the final step of acid secretion (the H^+/ K^+-ATPase pump).


Q: How to Store and Dispose of Ranitidine Disphar?

A: The medication should be stored at controlled room temperature (between 20 C and 25 C) and protected from light and moisture. For disposal, government guidance often suggests mixing unused or expired medication with an undesirable substance, such as dirt or coffee grounds, in a sealed container before placing it in household trash.


Q: How is Ranitidine Disphar stored properly?

A: The tablets must be kept in the original bottle with the cap tightly closed and the desiccant intact. It should be stored at controlled room temperature, protected from light and moisture, and kept out of the sight and reach of children.

How should Ranitidine Disphar be stored and disposed of?

How to Store and Dispose of Ranitidine Disphar?

Storage Requirement Official Regulatory Statement
Temperature & Protection Store at controlled room temperature (20 C to 25 C). The product must be protected from light and moisture and should avoid excessive heat.
Container & Stability The tablets must be kept in the original bottle with the desiccant intact and the cap securely and tightly closed immediately after removing a tablet. Discard unused tablets 3 months (90 days) after the initial opening or by the expiration date, whichever is sooner.
Disposal Instructions Unused or expired medication must be disposed of properly. Government guidance often advises against taking this medicine to a drug take-back location. Instead, consumers should mix the product with an undesirable substance (e.g., dirt, coffee grounds) in a sealed container before placing it in household trash.
Child Safety Keep the medicine out of the sight and reach of children (mandatory safety requirement).

These official regulatory statements strictly define the conditions under which the product must be stored, handled, and discarded to ensure stability. The rules emphasize maintaining a dry, light-protected environment and adherence to a strict post-opening discard timeline.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ranitidine Disphar found in:

A-Z Index: